SCHEMBL23326201

SCHEMBL23326201

COc1cc(C(=O)Nc2cc3ncc(Nc4ccccc4)nc3nc2C)cc(OC)c1OC

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.54
▸ KMT2A Q03164 5/20 0.54
▸ PDGFRB P09619 1/20 0.48
▸ PDGFRA P16234 1/20 0.48
▸ BRAF P15056 1/20 0.47
▸ MAPT P10636 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ PIK3CA P42336 1/20 0.46
▸ SMO Q99835 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23326225 0.87 PIK3CA (0.53) MEN1KMT2APDGFRBPDGFRAMAPT
SCHEMBL23326331 0.84 NPC1 (0.51) MEN1KMT2APDGFRBPDGFRAMAPT
SCHEMBL23326325 0.82 PIK3CA (0.58) MEN1KMT2APDGFRBPDGFRAMAPT
SCHEMBL23326308 0.82 PIK3CA (0.48) MEN1KMT2APDGFRBPDGFRAMAPT
SCHEMBL23344436 0.81 PIK3CA (0.52) MEN1KMT2APDGFRBPDGFRAMAPT
SCHEMBL23344453 0.80 PIK3CA (0.68) MEN1KMT2APDGFRBPDGFRAMAPT
SCHEMBL23326385 0.79 KMT2A (0.48) MEN1KMT2AMAPTPIK3CALMNA
SCHEMBL23344450 0.79 KCNQ3 (0.45) PDGFRBPDGFRASMN1; SMN2MAOBPIK3CA
SCHEMBL23326384 0.79 BRAF (0.54) MEN1KMT2ABRAFMAPTLMNA
SCHEMBL4349785 0.79 MEN1 (0.60) MEN1KMT2ABRAFMAOBPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11117894-B2 Pyridopyrazine compounds and uses thereof CITY OF HOPE (US) 2021-09-14 — — US disclosed
US-11117894-B2 Pyridopyrazine compounds and uses thereof CITY OF HOPE (US) 2021-09-14 — — US disclosed
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2021-05-13 — — US disclosed
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117894-B2 Pyridopyrazine compounds and uses thereof PDXK, DPYD, PNPO MEN1 4106/4885KMT2A 2474/4885PDGFRB 1526/4885
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF PDXK, DPYD, PNPO MEN1 4106/4885KMT2A 2474/4885PDGFRB 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback